Learn About Brixadi Treatment Information Guide

What Brixadi Is and How It Works

Brixadi is a prescription medication used to treat opioid use disorder (OUD). The medication was approved by the U.S. Food and Drug Administration (FDA) in December 2022, making it a relatively new option in the treatment landscape. Brixadi contains the active ingredient buprenorphine, which is a partial opioid agonist. This means it binds to opioid receptors in the brain but produces a milder effect than full opioids.

The primary purpose of Brixadi is to reduce cravings and withdrawal symptoms that people with opioid use disorder experience. When someone stops using opioids abruptly, they often face severe withdrawal symptoms including body aches, sweating, anxiety, and intense cravings. Brixadi works by partially activating opioid receptors, which satisfies the brain's need for opioid stimulation without producing the same "high" or level of dependence as other opioids. This dual action makes it valuable for both reducing drug-seeking behavior and managing withdrawal symptoms.

What sets Brixadi apart from other buprenorphine formulations is its delivery method. Brixadi is administered as a subcutaneous injection, meaning it is injected under the skin. Depending on the specific formulation, these injections may be given weekly or monthly. This is different from traditional buprenorphine medications like sublingual tablets or films that dissolve under the tongue. The injection approach offers several potential advantages for people managing their treatment.

Clinical trials showed that Brixadi reduced illicit opioid use significantly in study participants. In trials, patients receiving Brixadi had lower rates of positive urine drug screens for opioids compared to placebo groups. The medication has been shown to help people stay in treatment longer and experience fewer withdrawal symptoms.

Practical Takeaway: Brixadi is a prescription medication that uses buprenorphine delivered through subcutaneous injection to treat opioid use disorder by reducing cravings and withdrawal symptoms. Understanding how the medication works at a basic level can help people have informed conversations with healthcare providers about whether it might be appropriate for their situation.

Injection Schedules and Administration Methods

Brixadi is available in different formulations that allow for different injection schedules. The two main options are weekly injections and monthly injections. Healthcare providers work with patients to determine which schedule might work best based on individual circumstances, preferences, and medical history.

The weekly formulation contains 8 mg of buprenorphine per injection. Patients receiving weekly injections come to a healthcare facility or clinic once per week for their dose. This schedule requires more frequent clinic visits, but some people prefer it because they can adjust their treatment more quickly if side effects occur. The weekly schedule also provides more frequent contact with healthcare providers, which can be helpful for monitoring progress and addressing concerns.

The monthly formulation is available in different strengths: 64 mg and 128 mg per injection. These injections are administered once per month, meaning patients need to visit their healthcare provider only 12 times per year for medication doses. This less frequent schedule can reduce barriers to treatment for people who have transportation challenges, work schedules that make frequent clinic visits difficult, or who live far from treatment facilities. A 2023 study published in clinical trial data showed that monthly buprenorphine formulations had similar effectiveness rates to weekly formulations in maintaining treatment adherence.

The injection itself is relatively quick, typically taking just a few minutes. A healthcare provider injects Brixadi subcutaneously, which means under the skin but not into muscle. Common injection sites include the abdomen, upper arm, or thigh. Patients typically do not need to undress completely for the procedure. After receiving an injection, patients usually remain at the clinic for a brief period to ensure there are no immediate adverse reactions.

Practical Takeaway: Brixadi comes in weekly and monthly injection options. Understanding the differences between schedules can help people discuss with their healthcare provider which option might fit better with their lifestyle, work, and transportation circumstances.

Potential Side Effects and What to Expect

Like all medications, Brixadi can cause side effects. The most common side effects reported in clinical trials were mild to moderate and included injection site reactions, constipation, headache, and nausea. In clinical trials, approximately 35-40% of patients experienced some form of injection site reaction, though most were described as mild, such as slight redness, itching, or small bumps that resolved within a few days.

Injection site reactions are among the most frequently reported side effects. These reactions can include redness, swelling, itching, bruising, or mild pain at the spot where the needle entered the skin. In most cases, these reactions are temporary and resolve without treatment within a few days. Applying ice or a warm compress can sometimes reduce discomfort. More serious injection site reactions are rare but can include abscess formation or infection, which would require medical attention.

Constipation is another common side effect associated with buprenorphine medications, including Brixadi. This occurs because opioid medications slow the movement of the digestive system. People receiving Brixadi may need to increase their fiber intake, drink more water, or use over-the-counter stool softeners. In some cases, healthcare providers may recommend specific dietary changes or medications to manage constipation.

Less common but important side effects include respiratory depression (slowed breathing), especially when combined with other medications or substances that depress the central nervous system. People receiving Brixadi should inform their healthcare provider about all other medications they take, including over-the-counter medications, supplements, and any substances they use. Mixing Brixadi with benzodiazepines, alcohol, or other opioids can increase the risk of serious complications and should be discussed with a healthcare provider.

Withdrawal symptoms can occur if someone suddenly stops taking Brixadi or if the dose is reduced too quickly. This is different from a side effect—it is the body's reaction to the absence of the medication. Withdrawal symptoms may include anxiety, body aches, sweating, and insomnia. Healthcare providers typically taper doses gradually to prevent or minimize withdrawal symptoms when discontinuing treatment.

Practical Takeaway: While Brixadi generally has fewer severe side effects than many other medications, understanding common reactions like injection site reactions and constipation, plus the importance of informing providers about all medications and substances, helps people know what to expect and when to contact their healthcare provider.

How Brixadi Compares to Other Opioid Use Disorder Treatments

Several medications are currently used to treat opioid use disorder, and they work through different mechanisms. Buprenorphine, the active ingredient in Brixadi, has been used in other formulations for decades. Methadone is another long-established medication for OUD. Naltrexone is a third medication option. Each has different strengths and considerations, and the best choice depends on individual circumstances.

Methadone has been used to treat opioid use disorder since the 1960s. It is a full opioid agonist, meaning it fully activates opioid receptors in the brain. Methadone is highly effective at preventing withdrawal and reducing cravings, and decades of research support its use. However, methadone requires daily visits to a clinic for dosing in most cases, at least initially. Methadone also carries a higher risk of overdose than buprenorphine if someone takes more than prescribed or combines it with other substances. Approximately 15-16% of all opioid overdose deaths involve methadone, according to CDC data, despite methadone accounting for only about 5-10% of opioid use disorder treatment.

Naltrexone is an opioid antagonist, meaning it blocks opioid receptors rather than activating them. Extended-release naltrexone is available as an injection, similar to Brixadi. The advantage of naltrexone is that it has no abuse potential—it cannot produce a high. However, naltrexone must be started only after a person has completely detoxified from opioids, which can be challenging. If someone relapses and uses opioids while taking naltrexone, the naltrexone can precipitate severe withdrawal symptoms. About 20-30% of people prescribed naltrexone do not remain in treatment long-term, partly due to these factors.